Phase 3 N=1,647 Plaque Psoriasis Efficacy and Safety With Secukinumab
Plaque Psoriasis
Primary: Maintenance of PASI 90 Response at Week 52 in Participants With a PASI 90 Response at Week 24 — 552; 496 Participants — p=0.1499
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=129 A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Plaque Psoriasis
Psoriasis
Primary: Percent Change From Baseline in Psoriasis Assessment of Severity Index (PASI) at Week 12 — -28.043; -37.361 percentage change — p=0.8495
Phase 2 N=24 A Psoriasis Plaque Test Study With LEO 90100 Cutaneous Spray, Ointment, in Psoriasis Vulgaris
Psoriasis Vulgaris
Primary: Absolute Change in Total Clinical Score (TCS) of Clinical Signs (Sum of Erythema, Scaling and Infiltration) at End of Treatment Compared to Baseline — -6.00; -4.96…
Phase 1 N=24 A Plaque Test Study With LEO 35299 in Psoriasis Vulgaris
Psoriasis Vulgaris
Primary: Change in the Total Clinical Score From Baseline to Day 22 — -2.8; -1.9; -1.5; -1.8 units on a scale
Phase 4 N=124 Moderate to Severe Plaque Psoriasis With Scalp Involvement
Psoriasis
Primary: Percentage Change From Baseline in Psoriasis Scalp Severity Index at Week 12 — 20.4; 86.8 Percent change — p=<0.0001
Phase 4 N=25 Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color
Plaque Psoriasis · Psoriasis
Primary: Number of Patients Who Achieved Treatment Success — 4; 0 Participants
Phase 2 N=81 Topical CP-690,550 For Chronic Plaque Psoriasis
Psoriasis
Primary: Percent Change From Baseline in Target Plaque Severity Score (TPSS) at Week 4 — 2.38; -4.76; 2.48; -4.17 Percent Change
Phase 1 N=29 A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants
Psoriasis
Primary: Percentage (%) of Participants Who Achieved Greater Than or Equal (>=) to 75% Improvement From Baseline in Psoriasis Area Severity Index (PASI) Score at Week 12 — 5; 0…
Phase 3 N=174 Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement
Psoriasis
Primary: Percentage of Participants Achieving Palmoplantar Investigator's Global Assessment (ppIGA) of "Clear" or "Almost Clear" (0 or 1) With at Least a 2-point Reduction From…
Phase 2 N=24 A Short-contact Plaque Test Study With Daivobet® Gel in Psoriasis Vulgaris
Psoriasis Vulgaris
Primary: Change in Total Clinical Score From Baseline to Day 22 — -3.6; -3.7; -4.9; -1.3 units on a scale
Phase 4 N=20 Topical Psoriasis Study for Patients Receiving Biologic Therapy
Psoriasis
Primary: Psoriasis Severity — 4.25 units on a scale
Phase 4 N=352 Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy
Psoriasis
Primary: Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 90 (Defined as at Least 90% Improvement in PASI From Baseline) in Intent to Treat Population at…
Phase 4 N=20 The Effect of Enstilar Versus Vehicle on Target Lesions in Moderate Plaque Type Psoriasis Patients
Plaque Psoriasis
Primary: Change in Physicians Global Assessment (PGA) From Baseline to Week 2 and Week 4 — 20; 0; 0; 0 Participants
Phase 3 N=303 A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp
Psoriasis
Primary: Percentage of Participants With Scalp Physician Global Assessment (ScPGA) Score of Clear (0) or Almost Clear (1) With at Least a 2-Point Reduction From Baseline — 13.7…
Phase 4 N=100 Apremilast in Palmo-Plantar Psoriasis
Palmo-plantar Psoriasis
Primary: Palmoplantar Psoriasis Physician Global Assessment (PPPGA) of 0 or 1 — 7; 2 Participants
N/A N=660 Assessment of Long-Term Infliximab for Psoriasis (P05319)
Psoriasis
Primary: Number of Participants With a Psoriasis Area Sensitivity Index (PASI)-75 Response at Week 50 — 296 Participants
Phase 4 N=29 Apremilast 30mg Bid With Narrowband UVB in the Treatment of Plaque Psoriasis
Plaque Psoriasis
Primary: Number of Participants Maintaining Psoriasis Area Severity Index Score (PASI) 75 at Week 36 — 4; 2 participants
Phase 2 N=68 AN2728 Topical Ointment to Treat Mild-to-Moderate Plaque-Type Psoriasis
Psoriasis
Primary: Percentage of Participants Who Achieved Success in Physician's Global Assessment (PGA) of Disease Severity at Day 84 — 17.4; 13.6 percentage of participants
Phase 4 N=11 Evaluating the Efficacy and Tolerability of Application of Metaderm Product for the Treatment of Psoriasis
Psoriasis
Primary: Efficacy as Measured by the Mean Percentage Change in the Product of Static Physician Global Assessment (sPGA) and Body Surface Area (BSA). — 53.06; 65.6 percentage of…
Phase 4 N=12 A Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis
Psoriatic Nail · Psoriasis Vulgaris · Psoriasis
Primary: Mean Percent Change of mNAPSI (Modified Nail Area Psoriasis Severity Index) at Week 36 Compared to Baseline for All Nails. — 64.1 percentage of reduction in mNAPSI score…
Phase 2 N=31 Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis
Psoriasis-Type Psoriasis · Plaque-Type Psoriasis
Primary: Treatment Emergent Adverse Events (TEAEs) During the Treatment Phase — 25; 13; 3; 1 participants
Phase 2 N=71 CP-690-550 Ointment For Chronic Plaque Psoriasis
Psoriasis
Primary: Percent Change From Baseline in Target Plaque Severity Score (TPSS) at Week 4 — -53.97; -41.01; -24.26; -17.24 percent change
Phase 4 N=20 Use of Apremilast in Patients Who Are Dissatisfied With Stable Maintenance Topical Therapy
Plaque Psoriasis
Primary: Mean Change in Product of BSA (Body Surface Affected by Psoriasis) and sPGA (Static Physician Global Assessment) From Baseline to Week 16 — -9 score on a scale
Phase 3 N=595 Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy
Psoriasis
Primary: Percentage of Participants With a Static Physician Global Assessment (sPGA) Response at Week 16 During the Placebo-Controlled Phase — 4.1; 21.6 Percentage of…
Phase 2 N=471 Tofacitinib Ointment For Chronic Plaque Psoriasis
Psoriasis Vulgaris · Psoriasis
Primary: Percentage of Participants Achieving a PGA-C Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to (≥) 2 Grade/Point Improvement From Baseline at Week…
Phase 1 N=15 A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis
Psoriasis Vulgaris
Primary: Change From Baseline in Psoriatic Skin Thickness/Echo-Poor Band (EPB) for PF-06263276 4% Solution in Comparison to Corresponding Vehicle at Day 12 — 358.9; 353.1; 17.7…
N/A N=955 Observational Study Evaluating Etanercept (Enbrel®) In Subjects With Plaque-Type Psoriasis In Usual Care Settings
Psoriasis
Primary: Duration of Drug-Free Interval Prior to Treatment Cycle 2 — 12.6 weeks
Phase 2 N=28 Efficacy of Atorvastatin as Adjunctive Treatment for Chronic Plaque Type Psoriasis
Psoriasis
Primary: Mean Gross Change in Psoriasis Area and Severity Index (PASI) Scores From Baseline to the End of 6 Months — -2.15; -1.69 units on a scale
Phase 3 N=24 Safety and Efficacy of Infliximab in Palmoplantar Psoriasis
Palmoplantar Psoriasis
Primary: 75% Improvement in Modified Palmoplantar Pustulosis Area and Severity Index (m-PPPASI) From Day 0 — 1; 4 Participants
Phase 2 N=100 Multiple-loading Dose Regimen Study in Patients With Chronic Plaque-type Psoriasis
Chronic Plaque Psoriasis
Primary: Change From Baseline in Psoriasis Area and Severity Index (PASI) Scores — -12.46; -13.35; -18.02; -4.18 scores on a scale